Alimera Sciences To Present At Citi 2010 Global Health Care Conference
ATLANTA, May 20, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, President and Chief Executive Officer, is scheduled to present at the Citi 2010 Global Healthcare Conference, to be held May 26-27, 2010 at The Hilton New York Hotel in New York City.
Mr. Myers and Rick Eiswirth, Chief Financial Officer, will be available to respond to questions during a breakout session immediately following the presentation and to participate in one-on-one meetings with investors attending the conference.
Event: Citi 2010 Global Healthcare ConferenceDate: Thursday, May 27, 2010 Time: 3:30pm ET (Breakout: 4pm ET) Place: The Hilton New York Hotel, New York, NY (Sutton Parlor Center) The presentation will be webcast live through the investor relations section of Alimera Sciences' website at www.alimerasciences.com . A replay of the webcast will be available through August 25, 2010. About Alimera Sciences, Inc. Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently the Company is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate Iluvien® is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME), a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
CONTACT: The Ruth Group Investors Sara Pellegrino 646-536-7002 firstname.lastname@example.org Media Jason Rando 646-536-7025 email@example.com
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV